Adaptive Biotechnologies Corporation

NasdaqGS:ADPT Voorraadrapport

Marktkapitalisatie: US$758.0m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Adaptive Biotechnologies Toekomstige groei

Future criteriumcontroles 1/6

Adaptive Biotechnologies zal naar verwachting groeien in winst en omzet met respectievelijk 22.7% en 18.8% per jaar. De winst per aandeel zal naar verwachting groeien met 24.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -106.2% zijn.

Belangrijke informatie

22.7%

Groei van de winst

24.2%

Groei van de winst per aandeel

Life Sciences winstgroei17.5%
Inkomstengroei18.8%
Toekomstig rendement op eigen vermogen-106.2%
Dekking van analisten

Good

Laatst bijgewerkt02 Oct 2024

Recente toekomstige groei-updates

Recent updates

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Apr 03
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Feb 01
Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Nov 17
Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Oct 13
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Jul 06
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

May 05
Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Apr 15
We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Dec 13
Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system

Oct 11

Adaptive Biotechnologies announces $250M non-dilutive royalty financing

Sep 12

We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Aug 14
We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Apr 29
Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Adaptive Biotechnologies: Good Buy For Long-Term Investors

Apr 15

Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

Feb 26
Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

Jan 09
We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

Our First Assessment On Adaptive Biotechnologies

Dec 16

Winst- en omzetgroeiprognoses

NasdaqGS:ADPT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026265-115-23-946
12/31/2025207-152-54-1288
12/31/2024173-182-100-1668
6/30/2024169-213-137-129N/A
3/31/2024175-215-145-136N/A
12/31/2023170-225-167-156N/A
9/30/2023180-196-171-159N/A
6/30/2023190-191-170-155N/A
3/31/2023184-195-195-179N/A
12/31/2022185-200-200-184N/A
9/30/2022168-221-231-208N/A
6/30/2022160-232-241-209N/A
3/31/2022155-229-248-199N/A
12/31/2021154-207-254-193N/A
9/30/2021147-190-241-179N/A
6/30/2021133-171-234-182N/A
3/31/2021116-155-208-176N/A
12/31/202098-146-168-150N/A
9/30/202092-122-148-137N/A
6/30/202092-99-131-120N/A
3/31/202093-82-115-105N/A
12/31/201985-70194205N/A
9/30/201978-62215227N/A
6/30/201969-56235245N/A
3/31/201959-53243252N/A
12/31/201856-46-39-32N/A
12/31/201738-43N/A-35N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ADPT de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ADPT de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ADPT de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van ADPT ( 18.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van ADPT ( 18.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat ADPT binnen 3 jaar verliesgevend zal zijn.

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y